Golden points from Kala-azar control program (Health loksewa)
Kala-azar control programme
Ø Kala-azar is the
elimination program of Nepal.
Ø Kala-azar control
program is also regarded as priority one (P1) public health program.
Ø Kala-azar rapid
diagnostic kit (rK39) available up to PHCC level of program districts.
Ø Elimination of
Kala-azar means:- Annual incidence of Kala-azar to less than 1 case per 10,000
population at district level.
Ø Liposomal
amphotericin-B is first line drug for Kala-azar and available only up to
district hospital because L-AMB needs cold chain for storage.
Ø Kala-azar is a
vector borne disease caused by parasite Leishmania donovani, which is
transmitted by sandfly (Phlebotomus argentipes).
Ø It is also known as
black fever and visceral leishmaniasis.
Important dates:
|
1980AD |
Kala-azar first emerged in Nepal |
|
2005AD |
EDCD of DoHS formulated national plan for the elimination of Kala-azar |
|
2005-2008 |
Preparatory phase |
|
2008-2015 |
Attack phase |
|
2015 to onwards |
Consolidation phase |
Comparative
data:
|
|
2074/75 |
2075/76 |
2076/77 |
Bagmati |
Gandaki |
Karnali |
|
Trend of Kala-azar cases |
239 |
216 |
187 |
16 |
3 |
48 |
According to
annual report 2076/77:
Ø Kala-azar endemic
districts :- 23
Ø Kala-azar endemic
doubtful districts :- 46
Ø Kala-azar
non-endemic districts :- 8
Ø Total (23) endemic
districts :- 110 cases
Ø Total endemic
doubtful districts :- 76 cases
Ø Foreign case :- 1
case
Ø Highest number of
cases was reported from Kalikot i.e. 23.
Ø 3 cases of post
Kala-azar Leishmaniasis (PKDL) has been reported from Sarlahi, Palpa and
Morang.
Ø 22 cases of
Cutaneous leishmaniasis (CL) has been reported.
Major activities
in 2076/77:
Ø Case detection and
treatment
Ø RDT scaling up
Ø Use of liposomal
amphotericin-B as first line treatment regimen
Ø Indoor residual spraying
of priority affected area
Ø Orientation and
training
Ø National Kala-azar
technical working group meeting
Ø Disease
surveillance
Strategies:
Ø Early diagnosis and
complete treatment
Ø Integrated vector
management
Ø Effective disease
and vector surveillance
Ø Social mobilization
and partnerships
Ø Improve programme
management
Ø Clinical and
implementation research
Thanks for reading the Blog.
good note keep on going
ReplyDelete